bosentan anhydrous has been researched along with u 62840 in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (53.85) | 29.6817 |
| 2010's | 16 (41.03) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, P; Fleming, T; Lindenfeld, J; Lipicky, R | 1 |
| Maloney, JP | 1 |
| Mehta, S | 1 |
| Highland, KB; Mazur, J; Simpson, KN; Strange, C | 1 |
| Poon, M; Sulica, R | 1 |
| Frost, AE; Suleman, N | 1 |
| Howard, LS; Morrell, NW | 1 |
| Akram, MR; Black, CM; Coghlan, JG; Das, C; Davar, J; Denton, CP; Handler, CE; Smith, CJ; Williams, MH | 1 |
| Archer, SL; Michelakis, ED | 1 |
| Arneson, C; Barst, RJ; Galie, N; Jeffs, R; Naeije, R; Rubin, LJ; Simonneau, G | 1 |
| Beghetti, M | 1 |
| Channick, RN; Olschewski, H; Rubin, LJ; Seeger, W; Staub, T; Voswinckel, R | 1 |
| Criner, GJ; Farber, HW; Hill, NS; Klinger, JR; Preston, IR; Steiner, MK; Waxman, AB | 1 |
| Hachulla, E; Humbert, M; Launay, D | 1 |
| Gabbay, E; Reed, A; Williams, TJ | 1 |
| Baloira, A | 1 |
| Diaz-Guzman, E; Dweik, RA; Heresi, GA; Minai, OA | 1 |
| Park, MH | 1 |
| Benza, RL; Bourge, RC; Pamboukian, SV; Rayburn, BK; Tallaj, JA | 1 |
| Li, D; Matuschak, GM; Nayak, RP | 1 |
| Boonstra, A; Jacobs, W; Marcus, JT; Postmus, PE; Vonk-Noordegraaf, A | 1 |
| Park, MH; Rubin, LJ | 1 |
| Dingemanse, J; Gotzkowsky, SK; Lai, A; Laliberte, K; Mottola, D | 1 |
| Dalton, B; Gabbay, E; Keogh, A; Steele, P; Stewart, S; Strange, G; Wlodarczyk, J | 1 |
| Benza, RL; Channick, RN; McLaughlin, VV; Olschewski, H; Robbins, IM; Rubenfire, M; Rubin, LJ; Seeger, W; Tapson, VF; Voswinckel, R | 1 |
| Cleary, H; Edelman, K; López-Candales, A | 1 |
| Andreassen, AK; Gude, E; Solberg, OG; Ueland, T | 1 |
| Benza, RL; Channick, RN; McLaughlin, VV; Olschewski, H; Robbins, IM; Rubin, LJ; Seeger, W; Tapson, VF; Voswinckel, R | 1 |
| Daniels, CJ; Mueller, J; Smith, JS | 1 |
| Huang, XM; Yu, YP | 1 |
| Allen, RP; Arneson, C; Badesch, DB; Frantz, RP; Frost, AE; Galiè, N; Keogh, AM; Kermeen, F; Laliberte, K; Shapiro, SM; Sigman, J; Tapson, VF; Torres, F | 1 |
| McLaughlin, VV | 1 |
| Humbert, M; Jardim, C; Souza, R | 1 |
| Baloira Villar, A; Núñez Fernández, M; Pousada Fernández, G; Valverde Pérez, D | 1 |
| Bull, DA; Hatton, N; Ryan, JJ; Suksaranjit, P; Wilson, BD | 1 |
| Fan, R; Fan, Y; Ji, R; Penny, DJ; Varghese, NP; Wang, G; Zou, W | 1 |
| Chen, J; Liu, J; Qian, X; Tang, W; Xie, T; You, R; Zeng, F; Zhang, Y | 1 |
| Locatelli, I; Petrovič, M | 1 |
| Kam, CW; Ruiz, FE | 1 |
15 review(s) available for bosentan anhydrous and u 62840
| Article | Year |
|---|---|
Advances in the treatment of secondary pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Clinical Trials as Topic; Echocardiography; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2003 |
Drug therapy for pulmonary arterial hypertension: what's on the menu today?
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2003 |
Treatment of pulmonary arterial hypertension: a preliminary decision analysis.
Topics: Antihypertensive Agents; Bosentan; Decision Support Techniques; Epoprostenol; Fees, Pharmaceutical; Humans; Hypertension, Pulmonary; Markov Chains; Quality-Adjusted Life Years; Sulfonamides | 2003 |
Current medical treatment of pulmonary arterial hypertension.
Topics: Algorithms; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Platelet Aggregation Inhibitors; Sulfonamides | 2004 |
New therapeutic agents for pulmonary vascular disease.
Topics: Adult; Antihypertensive Agents; Arginine; Bosentan; Child; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Sulfonamides | 2005 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Child; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Phosphodiesterase Inhibitors; Receptors, Endothelin; Sulfonamides; Vasodilator Agents | 2006 |
[Pulmonary arterial hypertension and systemic sclerosis].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Cohort Studies; Echocardiography, Doppler; Epoprostenol; European Union; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prevalence; Prognosis; Purines; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Vasodilator Agents; World Health Organization | 2006 |
Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006.
Topics: Adolescent; Adult; Aged; Arterioles; Australia; Bosentan; Cardiac Catheterization; Diagnostic Imaging; Disease Progression; Dyspnea; Endothelin A Receptor Antagonists; Epoprostenol; Exercise Test; Female; Forecasting; Heart-Lung Transplantation; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Nitric Oxide; Piperazines; Prognosis; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction | 2008 |
Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Epoprostenol; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Time Factors; Treatment Outcome | 2010 |
[Progress in pharmacotherapy of pulmonary arterial hypertension in children].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bosentan; Calcium Channel Blockers; Child; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Sulfonamides | 2012 |
Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sildenafil Citrate; Vasodilator Agents | 2018 |
A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Topics: Adult; Antihypertensive Agents; Bayes Theorem; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Humans; Male; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Practice Guidelines as Topic; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Treatment Outcome | 2020 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
7 trial(s) available for bosentan anhydrous and u 62840
| Article | Year |
|---|---|
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Cohort Studies; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Injections, Subcutaneous; Male; Middle Aged; Placebos; Sulfonamides; Survival Rate; Treatment Outcome | 2006 |
Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Severity of Illness Index; Sulfonamides; Treatment Outcome; Vascular Resistance | 2006 |
Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Lung; Middle Aged; Physical Endurance; Pilot Projects; Severity of Illness Index; Sulfonamides; Walking | 2006 |
Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
Topics: Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Bosentan; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Epoprostenol; Female; Half-Life; Humans; Male; Middle Aged; Sulfonamides; Tandem Mass Spectrometry; Young Adult | 2010 |
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents; Young Adult | 2010 |
Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Double-Blind Method; Drug Therapy, Combination; Epoprostenol; Female; Headache; Humans; Hypertension, Pulmonary; Incidence; Longitudinal Studies; Male; Middle Aged; Nausea; Physical Endurance; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Young Adult | 2011 |
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Walking; Young Adult | 2012 |
17 other study(ies) available for bosentan anhydrous and u 62840
| Article | Year |
|---|---|
Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
Topics: Antihypertensive Agents; Bosentan; Contraindications; Drug Approval; Drug Interactions; Drug Monitoring; Endpoint Determination; Epoprostenol; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; United States; Vasodilator Agents | 2001 |
Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Long-Term Care; Male; Middle Aged; Substance Withdrawal Syndrome; Sulfonamides; Treatment Outcome | 2004 |
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Prostaglandins; Scleroderma, Systemic; Sulfonamides; Survival Analysis; Vasodilator Agents | 2006 |
[Pulmonary hypertension treatment: future prospects].
Topics: Administration, Intranasal; Administration, Oral; Animals; Bosentan; Drug Evaluation, Preclinical; Endothelin A Receptor Antagonists; Epoprostenol; Forecasting; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Isoxazoles; Life Expectancy; Lung Transplantation; Monocrotaline; Piperazines; Platelet-Derived Growth Factor; Purines; Randomized Controlled Trials as Topic; Rats; Sheep; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2007 |
Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Chi-Square Distribution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Parenteral; Male; Middle Aged; Piperazines; Prostaglandins; Purines; Retrospective Studies; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Sulfones; Treatment Outcome | 2008 |
Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Drug Therapy, Combination; Dyspnea; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Sulfonamides | 2008 |
Portopulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Epoprostenol; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Transplantation; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
The globalization of clinical trials in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome | 2010 |
Constrictive-like physiology in severe pulmonary hypertension: the effect of the Valsalva maneuver.
Topics: Adult; Antihypertensive Agents; Bosentan; Constriction, Pathologic; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Sulfonamides; Ultrasonography; Valsalva Maneuver | 2011 |
[Treatment of idiopathic pulmonary arterial hypertension].
Topics: Adult; Airway Resistance; Antihypertensive Agents; Bosentan; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Lung Volume Measurements; Male; Middle Aged; Oxygen Consumption; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Pulmonary arterial hypertension in the setting of pregnancy: a case series and standard treatment approach.
Topics: Adult; Algorithms; Anticoagulants; Antihypertensive Agents; Bosentan; Enoxaparin; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Postnatal Care; Pregnancy; Pregnancy Complications, Cardiovascular; Prenatal Care; Sulfonamides; Young Adult | 2012 |
Has the 6-min walk distance run its course?
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Sulfonamides | 2012 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial Primary Pulmonary Hypertension; Fenfluramine; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Iloprost; Phenylpropionates; Piperazines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridazines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Thiazoles; Vasodilator Agents | 2013 |
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Eisenmenger syndrome with unrepaired patent ductus arteriosus.
Topics: Blood Transfusion; Bosentan; Diagnostic Imaging; Dobutamine; Ductus Arteriosus, Patent; Eisenmenger Complex; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Menorrhagia; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Tomography, X-Ray Computed; Vasodilator Agents; Young Adult | 2015 |
Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Child, Preschool; Codon, Nonsense; Epoprostenol; Growth Differentiation Factor 2; Growth Differentiation Factors; Homozygote; Humans; Hypertension, Pulmonary; Male; Mexican Americans; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin | 2016 |